Life Technologies Bolsters its 60 Percent Market Share Lead in Benchtop Sequencers
News Feb 20, 2013
Life Technologies Corporation announced a dozen innovative new products for the Ion Torrent™ platform that will make sequencing faster, simpler and more accessible for scientists, driving discovery and advancing clinical research around the world.
"These new products continue the pace of relentless innovation that in just two years enabled Ion Torrent™ semiconductor sequencing technology to scale more than 1,000-fold and gain a 60 percent market share of benchtop sequencers," said Dr. Jonathan M. Rothberg, Ion Torrent Founder and CEO. "More than 90 peer-reviewed publications and the world's largest online sequencing community, with over 15,000 members, reflect the huge demand for faster, simpler and more affordable sequencing."
Ion Torrent™ technology continues to simplify and automate key workflows, decreasing turnaround times and expanding access to next-generation sequencing for both basic and translational researchers.
• Ion Library Equalizer™ Kits eliminate the need for library quantification and library dilutions prior to clonal amplification for Ion AmpliSeq™ DNA and Ion genomic fragment libraries. The kit reduces hands-on time, sample variability and reagent cost, while increasing processing speed for high-throughput applications.
• Ion TargetSeq™ Exome Rapid Protocol reduces the capture step to just 16 hours, enabling whole human exome enrichment and sequencing on the Ion Proton™ Sequencer in as little as a day and a half, making the Ion Exome sequencing workflow the fastest method for performing human exome sequencing. The protocol is now available from Ion field application specialists.
• Ion AmpliSeq™ RNA Library Kit requires as little as 500 pg of unfixed RNA and 5 ng of FFPE RNA and is compatible with Ion Express™ Barcode Modules for multiplexing multiple samples on a single Ion semiconductor sequencing chip.
• Ion Total RNA-Seq Kit for AB Library Builder™ System enables the analysis of either whole transcriptome or small RNA expression with a single reagent kit. The kit requires as little as 500 ng of total RNA, or as little as 50 ng of enriched small RNA.
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE